Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Tuberculosis

  Free Subscription


03.12.2018

15 Clin Infect Dis
1 J Infect Dis
1 JAMA
1 Lancet Infect Dis
8 PLoS One
1 Respir Med


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Clin Infect Dis

  1. GUMBO T, Alffenaar JC
    Pharmacokinetic/Pharmacodynamic Background and Methods and Scientific Evidence Base for Dosing of Second-line Tuberculosis Drugs.
    Clin Infect Dis. 2018;67.
    PubMed     Text format     Abstract available

  2. GANMAA D, Khudyakov P, Buyanjargal U, Jargalsaikhan B, et al
    Prevalence and determinants of QuantiFERON-diagnosed tuberculosis infection in 9,810 Mongolian schoolchildren.
    Clin Infect Dis. 2018 Nov 27. pii: 5210883. doi: 10.1093.
    PubMed     Text format     Abstract available

  3. CUBILLOS-ANGULO JM, Arriaga MB, Silva EC, Muller BLA, et al
    Polymorphisms in TLR4 and TNFA and Risk of Mycobacterium tuberculosis Infection and Development of Active Disease in Contacts of Tuberculosis Cases in Brazil: A Prospective Cohort Study.
    Clin Infect Dis. 2018 Nov 24. pii: 5204461. doi: 10.1093/cid/ciy1001.
    PubMed     Text format     Abstract available

  4. DESHPANDE D, Srivastava S, Nuermberger E, Koeuth T, et al
    Multiparameter Responses to Tedizolid Monotherapy and Moxifloxacin Combination Therapy Models of Children With Intracellular Tuberculosis.
    Clin Infect Dis. 2018;67.
    PubMed     Text format     Abstract available

  5. DESHPANDE D, Pasipanodya JG, Mpagama SG, Srivastava S, et al
    Ethionamide Pharmacokinetics/Pharmacodynamics-derived Dose, the Role of MICs in Clinical Outcome, and the Resistance Arrow of Time in Multidrug-resistant Tuberculosis.
    Clin Infect Dis. 2018;67.
    PubMed     Text format     Abstract available

  6. PASIPANODYA JG, Smythe W, Merle CS, Olliaro PL, et al
    Artificial intelligence-derived 3-Way Concentration-dependent Antagonism of Gatifloxacin, Pyrazinamide, and Rifampicin During Treatment of Pulmonary Tuberculosis.
    Clin Infect Dis. 2018;67.
    PubMed     Text format     Abstract available

  7. DESHPANDE D, Pasipanodya JG, Srivastava S, Bendet P, et al
    Gatifloxacin Pharmacokinetics/Pharmacodynamics-based Optimal Dosing for Pulmonary and Meningeal Multidrug-resistant Tuberculosis.
    Clin Infect Dis. 2018;67.
    PubMed     Text format     Abstract available

  8. DESHPANDE D, Alffenaar JC, Koser CU, Dheda K, et al
    d-Cycloserine Pharmacokinetics/Pharmacodynamics, Susceptibility, and Dosing Implications in Multidrug-resistant Tuberculosis: A Faustian Deal.
    Clin Infect Dis. 2018;67.
    PubMed     Text format     Abstract available

  9. DESHPANDE D, Pasipanodya JG, Mpagama SG, Bendet P, et al
    Levofloxacin Pharmacokinetics/Pharmacodynamics, Dosing, Susceptibility Breakpoints, and Artificial Intelligence in the Treatment of Multidrug-resistant Tuberculosis.
    Clin Infect Dis. 2018;67.
    PubMed     Text format     Abstract available

  10. FALZON D, Jaramillo E, Gilpin C, Weyer K, et al
    The Role of Novel Approaches and New Findings in the Pharmacology of Tuberculosis Medicines in Improving Treatment Outcomes.
    Clin Infect Dis. 2018;67.
    PubMed     Text format    

  11. SRIVASTAVA S, Deshpande D, Nuermberger E, Lee PS, et al
    The Sterilizing Effect of Intermittent Tedizolid for Pulmonary Tuberculosis.
    Clin Infect Dis. 2018;67.
    PubMed     Text format     Abstract available

  12. MAGOMBEDZE G, Pasipanodya JG, Srivastava S, Deshpande D, et al
    Transformation Morphisms and Time-to-Extinction Analysis That Map Therapy Duration From Preclinical Models to Patients With Tuberculosis: Translating From Apples to Oranges.
    Clin Infect Dis. 2018;67.
    PubMed     Text format     Abstract available

  13. SRIVASTAVA S, Deshpande D, Magombedze G, Gumbo T, et al
    Efficacy Versus Hepatotoxicity of High-dose Rifampin, Pyrazinamide, and Moxifloxacin to Shorten Tuberculosis Therapy Duration: There Is Still Fight in the Old Warriors Yet!
    Clin Infect Dis. 2018;67.
    PubMed     Text format     Abstract available

  14. STURKENBOOM MGG, Simbar N, Akkerman OW, Ghimire S, et al
    Amikacin Dosing for MDR Tuberculosis: A Systematic Review to Establish or Revise the Current Recommended Dose for Tuberculosis Treatment.
    Clin Infect Dis. 2018;67.
    PubMed     Text format     Abstract available

  15. BOLHUIS MS, Akkerman OW, Sturkenboom MGG, Ghimire S, et al
    Linezolid-based Regimens for Multidrug-resistant Tuberculosis (TB): A Systematic Review to Establish or Revise the Current Recommended Dose for TB Treatment.
    Clin Infect Dis. 2018;67.
    PubMed     Text format     Abstract available


    J Infect Dis

  16. SINHA P, Davis J, Saag L, Wanke C, et al
    Undernutrition and Tuberculosis: Public Health Implications.
    J Infect Dis. 2018 Nov 22. pii: 5197537. doi: 10.1093.
    PubMed     Text format     Abstract available


    JAMA

  17. SLOMSKI A
    Vaccine Prevents Active Tuberculosis.
    JAMA. 2018;320:2068.
    PubMed     Text format    


    Lancet Infect Dis

  18. LEE JK, Lee JY, Kim DK, Yoon HI, et al
    Substitution of ethambutol with linezolid during the intensive phase of treatment of pulmonary tuberculosis: a prospective, multicentre, randomised, open-label, phase 2 trial.
    Lancet Infect Dis. 2018 Nov 23. pii: S1473-3099(18)30480.
    PubMed     Text format     Abstract available


    PLoS One

  19. GASHU Z, Jerene D, Datiko DG, Hiruy N, et al
    Seasonal patterns of tuberculosis case notification in the tropics of Africa: A six-year trend analysis in Ethiopia.
    PLoS One. 2018;13:e0207552.
    PubMed     Text format     Abstract available

  20. CLOETE R, Kapp E, Joubert J, Christoffels A, et al
    Molecular modelling and simulation studies of the Mycobacterium tuberculosis multidrug efflux pump protein Rv1258c.
    PLoS One. 2018;13:e0207605.
    PubMed     Text format     Abstract available

  21. ABRAHAM PR, Devalraju KP, Jha V, Valluri VL, et al
    PPE17 (Rv1168c) protein of Mycobacterium tuberculosis detects individuals with latent TB infection.
    PLoS One. 2018;13:e0207787.
    PubMed     Text format     Abstract available

  22. LEE CU, Chong S, Choi HW, Choi JC, et al
    Quantitative image analysis using chest computed tomography in the evaluation of lymph node involvement in pulmonary sarcoidosis and tuberculosis.
    PLoS One. 2018;13:e0207959.
    PubMed     Text format     Abstract available

  23. HERMES R, Saragusty J, Moser I, Barth SA, et al
    Differential detection of tuberculous and non-tuberculous mycobacteria by qPCR in lavage fluids of tuberculosis-suspicious white rhinoceros.
    PLoS One. 2018;13:e0207365.
    PubMed     Text format     Abstract available

  24. MBUTHIA GW, Olungah CO, Ondicho TG
    Health-seeking pathway and factors leading to delays in tuberculosis diagnosis in West Pokot County, Kenya: A grounded theory study.
    PLoS One. 2018;13:e0207995.
    PubMed     Text format     Abstract available


  25. Correction: Rv1460, a SufR homologue, is a repressor of the suf operon in Mycobacterium tuberculosis.
    PLoS One. 2018;13:e0208568.
    PubMed     Text format     Abstract available

  26. MICHELET L, de Cruz K, Karoui C, Tambosco J, et al
    Second line molecular diagnosis for bovine tuberculosis to improve diagnostic schemes.
    PLoS One. 2018;13:e0207614.
    PubMed     Text format     Abstract available


    Respir Med

  27. SILVA DR, Sotgiu G, D'Ambrosio L, Pereira GR, et al
    Diagnostic performances of the Xpert MTB/RIF in Brazil.
    Respir Med. 2018;134:12-15.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Tuberculosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: